The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials

Figures & data

Table 1 Serious adverse events in the Salford-COPD pRCT

Event	FF/VI (N=1,396) N (%)	Usual Care (N=1,403) N (%)
Cardiovascular SAE
Any event	108 (8)	107 (8)
Arrhythmia	52 (4)	54 (4)
Heart failure	28 (2)	28 (2)
Cardiac ischemia	34 (2)	33 (2)
Hypertension	0	1 (<1)
Stroke	21 (2)	25 (2)
Respiratory SAE
Pneumonia	94 (7)	83 (6)
Lower respiratory tract infection	64 (5)	58 (4)
Chemistries SAE
Glucose level	23 (2)	16 (1)
Potassium level	2 (<1)	2 (<1)
General SAE
Decreased bone density	45 (3)	45 (3)
Hypersensitivity	10 (1)	10 (1)
Steroid-associated changes	2 (<1)	2 (<1)
Local glucocorticoid effects	0	1 (<1)

Note: Adapted from N Engl J Med. Vestbo J, Leather D, Diar Bakerly N, et al; Salford Lung Study Investigators. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. 375(13):1253–1260. Copyright © 2016 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.³⁶

Abbreviations: FF, fluticasone furoate; VI, vilanterol; SAE, serious adverse events; pRCT, pragmatic randomized controlled trial.

VestboJLeatherDDiar BakerlyNSalford Lung Study InvestigatorsEffectiveness of fluticasone furoate-vilanterol for COPD in clinical practiceN Engl J Med2016375131253126027593504

 PubMed Web of Science ®Google Scholar